论文部分内容阅读
本组从1990年6月至12月对肝硬化、肝癌患者进行了血清β_2微球蛋白(β_2m)的测定,将其结果作对比分析,并探讨其临床意义。材料与方法一、病例选择:所有病例均为住院病人。诊断标准:(一)肝硬化失代偿期:(1)门静脉高压所产生的侧支循环形成,脾大、脾功能亢进及腹水等;(2)肝功能损害所引起的白蛋白降低、水肿、腹水、黄疸及肝性脑病等。(二)原发性肝癌:诊断标准根据上海市肝癌协作组(1975)制定的原发性肝癌临床诊断标准。二、测定项目: 1.血清β_2m:采用北京中国原子能科学院生产的~(125)I—β_2微球蛋白免疫药盒,用放射免疫法测定。 2.肾功能(BUN Cr)及肝功能试验检查。
This group from June 1990 to December of cirrhosis, liver cancer in patients with serum β_2 microglobulin (β_2m) determination, the results for comparative analysis, and to explore its clinical significance. Materials and methods First, the case selection: All cases are inpatients. Diagnostic criteria: (a) cirrhosis decompensation: (1) collateral circulation generated by portal hypertension, splenomegaly, hypersplenism and ascites; (2) decreased liver function caused by albumin, edema , Ascites, jaundice and hepatic encephalopathy. (B) of the primary liver cancer: diagnostic criteria based on the Shanghai Liver Cooperative Group (1975) to develop a clinical diagnostic criteria for primary liver cancer. Second, the determination of the project: 1. Serum β_2m: using Beijing Institute of Atomic Energy produced ~ (125) I-β 2 microglobulin immune kit, measured by radioimmunoassay. 2. Renal function (BUN Cr) and liver function tests.